On Jun 7, 4:07 pm, JRStern <JRSt...@foobar.invalid> wrote:
> On Thu, 07 Jun 2012 01:14:17 -0600, Bohgosity BumaskiL
>
> <
brewh...@freenet.edmonton.ab.ca> wrote:
> >This is a set of reports that probably inspired the Wiley issue:
> >
http://www.ncbi.nlm.nih.gov/pubmed/22398059
> >Anti-TNF in bowels is blocking TNF in the bowels.
>
> So somehow the particular anti-TNF drugs used for IBD manage to only
> affect the bowel, and yet shift the behavior of TNF in the skin?
>
> Well, not something anyone would have guessed would happen, and I'd
> like to see rather some more MOA before even believing it.
>
> J.
J,
Well it's not a logic non sequitur (almost) more of a comedic one IMO.
LoL
http://en.wikipedia.org/wiki/Tumor_necrosis_factors#Family_members
http://en.wikipedia.org/wiki/MAb#Discovery
While i adhere to Élie Metchnikoff in terms of lactic acid loving gut
bacteria,
i'm not impressed with TNF blockers thusly.
http://en.wikipedia.org/wiki/%C3%89lie_Metchnikoff#Research
[...] Mechnikov also developed a theory that aging is caused by toxic
bacteria in the gut and that lactic acid could prolong life. Based on
this theory, he drank sour milk every day. He wrote three books:
Immunity in Infectious Diseases, The Nature of Man, and The
Prolongation of Life: Optimistic Studies, the last of which, along
with Metchnikoff's studies into the potential life-lengthening
properties of lactic acid bacteria (Lactobacillus delbrueckii subsp.
bulgaricus), inspired Japanese scientist Minoru Shirota to begin
investigating the causal relationship between bacteria and good
intestinal health, which eventually led to the worldwide marketing of
Kefir and other fermented milk drinks, or probiotics.
<snip>
To bad he didn't have vitamin D3 supplements back then. Might have
made it to 122. LOL
Hey... for BB... my beans have kicked in to GEAR and i'm now
Farting PROUDLY...Thanks to Benjamin Franklin!
It only took six days of eating BEANs. I now wonder why it took so
long?
Is my Gut flora askew for FARTing? Why did it take so long? Is that
normal?
OK... Let's look at this mAb thingy pooh! Why worry about a ill WIND!
WE need his pmid from above:
ok
http://www.ncbi.nlm.nih.gov/pubmed/22398059
J Crohns Colitis. 2012 Jun;6(5):518-23. Epub 2011 Nov 13.
Induction of psoriasis with anti-TNF agents in patients with
inflammatory bowel disease: A report of 21 cases.
Guerra I, Algaba A, Pérez-Calle JL, Chaparro M, Marín-Jiménez I,
García-Castellanos R, González-Lama Y, López-Sanromán A, Manceñido N,
Martínez-Montiel P, Quintanilla E, Taxonera C, Villafruela M, Romero-
Maté A, López-Serrano P, Gisbert JP, Bermejo F.
Source
Digestive Diseases Department, Hospital de Fuenlabrada, Spain.
Abstract
AIM:
Anti-tumor necrosis factor (TNF)-alpha agents are widely used for the
treatment of both inflammatory bowel disease (IBD) and psoriasis.
Psoriatic skin lesions induced by anti-TNF have been described in
patients with IBD. We report a case series of psoriasis induced by
anti-TNF agents in IBD patients.
METHODS:
Systematic analysis of cases of psoriasis induced by anti-TNF in an
IBD patient cohort in tertiary hospitals of Madrid.
RESULTS:
A total of 21 of 1294 patients with IBD treated with anti-TNF-alpha
agents developed drug-induced psoriasis (cumulative incidence 1.62%;
95% CI 1.06%-2.47%): 14 patients with infliximab and 7 with
adalimumab; seventeen with Crohn's disease, 4 with ulcerative colitis.
The onset of skin lesions varied in a wide range of time (after a mean
13±8 doses). The most frequent site of skin lesions was the limbs
(62%) followed by the trunk (48%) and the scalp (43%). The psoriasis
phenotypes were plaque psoriasis (57%), scalp (14%), palmoplantar
pustulosis (14%), pustular generalized psoriasis (5%), guttate (5%)
and inverse (5%). Four patients interrupted the anti-TNF treatment,
and that led to the complete regression of lesions in 1 of them. The
other 17 patients were maintained on anti-TNF therapy and managed with
topical steroids.
CONCLUSION:
Psoriatic lesions can be induced by anti-TNF drugs. Plaque psoriasis
on the extremities and trunk were the most frequent presentations in
our series. Topical steroid treatment is effective in most patients.
Anti-TNF discontinuance may be reserved for patients with severe
psoriasis or patients without response to topical therapy.
PMID: 22398059
Those 1294 ibd cases with 21 onsets to posriasis being .01622% isn't
screaming anything in particular to ME much.
NOT 1.6% but .016 percent. And is that par for the course of all
mAb's and psor de novo onset?
How many out of 100 onset from strep or lithium or or or or or or...
And how many have a complete remission?
WE WISH... i would try the damn things with the hope of stopping them
for that effect! LOL
Oddly one of 21 who stopped TNF blockers did have a complete remission
which i've read for many cases so far.
So?
Lucky so and so... but i'm farting proudly in he MEAN time... <G<
Number 1 we don't know if these 21 had other drugs (lithium based
or ?) that may have caused an onset.
Certainly, TNF blocker's and TNF receptors are more of a question mark
for those who take them.
LOL
For BB i doubt even if he had full blown psoriasis, he would get any
TNF blocking mAb as Canadian meds might go for FAE's for high severity
psoriasis IMO.
I'm not going on an EASTER EGG hunt for that one btw.
Till psor or IBD/crohn's/UC mAbs go generic, FAE's are more economical
and expedient for CANADIAN healthCARE unless they come south for mAb's
at their own expense... LOL
But iirc i did read some mAb's are in the UK healthcare system now.
OK.. #'s mean things... like words and you know about ACTIONS..
So i'm acting...on mAb.. <w>
While BB blames mAb it's still a gut flora trip and some stuPidly
glycan IMO.
OH and genetics.. of course.
269 hits: psoria* ulcerative colitis- pubmed
http://www.ncbi.nlm.nih.gov/pubmed?term=psoria*%20ulcerative%20colitis
633 hits: psoria* + crohn's - pubmed
http://www.ncbi.nlm.nih.gov/pubmed?term=psoria*%20crohn's
91 hits: ibd + psoria* -pubmed
http://www.ncbi.nlm.nih.gov/pubmed?term=psoria*%20ibd
1,052 hits: psoria* + infliximab
http://www.ncbi.nlm.nih.gov/pubmed?term=psoria*%20infliximab
7 of 1,052 have: de novo
http://www.ncbi.nlm.nih.gov/pubmed?term=psoria*%20infliximab%20de%20novo
#2 of 7
http://www.ncbi.nlm.nih.gov/pubmed/21752492
J Am Acad Dermatol. 2011 Jul 11.
Psoriasis and palmoplantar pustulosis associated with tumor necrosis
factor-α inhibitors: The Mayo Clinic experience, 1998 to 2010.
Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR.
Source
Mayo Medical School, College of Medicine, Mayo Clinic, Rochester,
Rochester, Minnesota.
Abstract
BACKGROUND:
Tumor necrosis factor (TNF)-α antagonists have been associated with
the induction of de novo or worsening psoriasis.
OBJECTIVE:
We sought to retrospectively examine the clinical characteristics and
outcomes of patients with psoriasis associated with anti-TNF-α
therapy.
METHODS:
We performed a retrospective review of patients with new-onset or
worsening psoriasis during TNF-α inhibitor therapy between 1998 and
2010.
RESULTS:
Of the 56 patients (mean age at psoriasis onset, 48.1 years), 41 (73%)
were female. In all, 22 patients (39%) had Crohn's disease and 14
(25%) had rheumatoid arthritis. Thirty patients (54%) were treated
with infliximab, 19 (34%) with adalimumab, and 7 (12%) with
etanercept. New-onset or worsening psoriasis occurred after a mean
treatment duration of 17.1 months. Plaque psoriasis (n = 27),
palmoplantar pustulosis (n = 25), scalp psoriasis (n = 12),
generalized pustular psoriasis (n = 7), erythrodermic psoriasis (n =
2), and inverse psoriasis (n = 2) were the cutaneous presentations.
Among the 39 patients for whom full treatment response data were
available, 33 (85%) had a complete or partial response; combined
response rates (complete and partial) were slightly higher among those
who discontinued anti-TNF-α therapy (16 of 17 patients [94%]) than
among those who continued anti-TNF-α therapy (17 of 22 patients
[77%]).
LIMITATIONS:
Retrospective nature, possible referral bias, and lack of complete
follow-up for some patients are limitations.
CONCLUSION:
Although some patients sufficiently controlled their psoriasis while
continuing anti-TNF-α therapy, those who discontinued therapy achieved
higher rates of complete response. Further studies should explore the
efficacy and safety of switching to an alternative anti-TNF-α agent.
PMID: 21752492
IF we had FAE in this country then wouldn't that make SENSE? LOL
12 hits: psoria* monoclonal antibodies de novo- pubmed:
http://www.ncbi.nlm.nih.gov/pubmed?term=psoria*%20%20monoclonal%20antibodies%20de%20novo
886 hits: monoclonal antibodies de novo
http://www.ncbi.nlm.nih.gov/pubmed?term=%20monoclonal%20antibodies%20de%20novo
So tnf blockers (mAbs) cause a lot of de novo cases of DISease.
And i'm not charged uP or blowing an ILL wind for these little money
maker's for big PHARMA.
They do have to pay for creating these drugs.
But IMO it's time to move on... like George Soros and obama did.
And it's time for obama to move on... LOL
Did you hear about that sarah parker and anna wintour supper for
raising bucks? LOL
Wow... i'd pay two cents to meet two complete... nevermind.
And to think i disliked TNF.... it even looks better thinking about
the latter.. LOL
randall.. isn't TNF systemic or maybe for dumbocraps
it is in their rectal regions? LOL